Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Fisher Asset Management LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 134.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 31,726 shares of the biotechnology company’s stock after purchasing an additional 18,181 shares during the quarter. Fisher Asset Management LLC’s holdings in BioMarin Pharmaceutical were worth $1,718,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in BMRN. Sittner & Nelson LLC boosted its position in BioMarin Pharmaceutical by 6.9% in the second quarter. Sittner & Nelson LLC now owns 3,100 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 200 shares in the last quarter. Grandfield & Dodd LLC increased its holdings in shares of BioMarin Pharmaceutical by 1.2% during the third quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock worth $1,027,000 after buying an additional 217 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical by 3.4% during the third quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock worth $387,000 after buying an additional 235 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of BioMarin Pharmaceutical by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 38,890 shares of the biotechnology company’s stock valued at $2,138,000 after acquiring an additional 250 shares during the last quarter. Finally, New Wave Wealth Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 2.5% in the third quarter. New Wave Wealth Advisors LLC now owns 11,910 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 288 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Up 0.9%

NASDAQ BMRN opened at $61.12 on Friday. The company has a market cap of $11.75 billion, a price-to-earnings ratio of 34.34, a PEG ratio of 0.53 and a beta of 0.25. The company has a current ratio of 5.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.10. The company has a 50 day moving average of $58.92 and a 200-day moving average of $56.27. BioMarin Pharmaceutical Inc. has a 1-year low of $50.76 and a 1-year high of $73.51.

Insider Buying and Selling

In related news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the sale, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BMRN. HC Wainwright reduced their target price on shares of BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a research note on Tuesday, February 24th. Canaccord Genuity Group increased their price objective on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Wells Fargo & Company raised their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Barclays lifted their target price on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research report on Tuesday. Fifteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $89.64.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.